Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA268151 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:aCGH profiles of parental and oxaliplatin resistant colorectal cancer and ovarian cancer cell lines
| PRJNA125563 | ENA
Project description:RNA sequence, Comparison of platinum sensitive and resistant ovarian cancer cell lines
| PRJDB15061 | ENA
Project description:microRNA profiling of trifluridine resistant colorectal cancer cell lines and parental cell lines
| PRJNA379673 | ENA
Project description:mRNA profiling of trifluridine resistant colorectal cancer cell lines and parental cell lines
| PRJNA379674 | ENA
Project description:Parental vs. BRAFi Resistant Melanoma Cell Lines
| PRJNA198428 | ENA
Project description:Gene expression profiles of parental and chemotherapy-resistant colon cancer cell lines.
| PRJNA181264 | ENA
Project description:Chemoresistance remains the major barrier to effective ovarian cancer treatment. The molecular features and associated biological functions of this phenotype remain poorly understood. We developed carboplatin resistant cell line models using OVCAR5 and CaOV3 cell lines with the aim of identifying chemoresistance-specific molecular features. Chemotaxis and CAM invasion assays revealed enhanced migratory and invasive potential in OVCAR5 resistant, compared to parental cells lines. Mass spectrometry analysis was used to analyse the metabolome and proteome of these cell lines and was able to separate these populations based on their molecular features. It revealed signalling and metabolic perturbations in chemoresistant cell lines. Comparison with the proteome of patient derived primary ovarian cancer cells grown in culture showed a shared dysregulation of cytokine and type 1 interferon signalling, potentially revealing a common molecular feature of chemoresistance. A comprehensive analysis of a larger patient cohort, including advanced in vitro and in vivo models, promises to help better understand the molecular mechanisms of chemoresistance and associated enhancement of migration and invasion.
2022-08-11 | PXD034246 | Pride
Project description:<p>BRCA1 mutations are a hallmark of hereditary ovarian cancer, strongly linked to deficiencies in homologous recombination (HR) DNA repair and impaired DNA replication fork protection. However, its roles in cancer progression beyond maintaining genomic integrity remain poorly understood. Through metabolomics approaches, we found BRCA1-deficiency strikingly increased choline metabolism. Loss of BRCA1 promotes choline uptake through upregulating choline transporter-like protein 4 (CTL4). BRCA1 directly binds and recruits EZH2-mediated H3K27Me3 deposition to CTL4 promoter. CTL4 was therefore overexpressed in ovarian cancer tissues with BRCA1 mutations. Furthermore, BRCA1-deficiency significantly promotes ovarian cancer invasion, while inhibition of CTL4 reverses the high metastatic potential of BRCA1-deficient ovarian cancer cells, suggesting the functionality and specificity of CTL4 as a therapeutic target. Additionally, we discovered that phosphocholine, the choline metabolite increased by CTL4 overexpression, interacted with and stabilized the epithelial-to-mesenchymal transition inducer FAM3C in BRCA1-deficient ovarian cancer cells. Importantly, we identified a potent CTL4 inhibitor, DT-13, which significantly reduces choline metabolism and effectively suppresses metastasis in BRCA1-deficient ovarian cancers. Therefore, our study uncovers a mechanism underlying metastasis in BRCA1-deficient cancers and identifies CTL4 as a therapeutic target for metastatic ovarian cancer patients with BRCA1 mutations.</p>
2026-05-15 | MTBLS12245 | MetaboLights
Project description:Comparison between HuT78 parental and romidpepsin-selected cell lines
| PRJNA192835 | ENA
Project description:Gene expression profiles of oxaliplatin resistant colorectal cancer and ovarian cancer cell lines
| PRJNA120157 | ENA